Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis
Dietary flavonols may play an important role in the adjunct therapy of chronic inflammation. The availability of therapeutic formulations of pentahydroxyflavone glycoside, rutoside (RU), led us to investigate the ability of this molecule to modulate the release of various proinflammatory mediators f...
Gespeichert in:
| Veröffentlicht in: | Arthritis research & therapy 2008-01, Vol.10 (1), p.R19-R19, Article R19 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | R19 |
|---|---|
| container_issue | 1 |
| container_start_page | R19 |
| container_title | Arthritis research & therapy |
| container_volume | 10 |
| creator | Kauss, Tina Moynet, Daniel Rambert, Jérôme Al-Kharrat, Abir Brajot, Stephane Thiolat, Denis Ennemany, Rachid Fawaz, Fawaz Mossalayi, M Djavad |
| description | Dietary flavonols may play an important role in the adjunct therapy of chronic inflammation. The availability of therapeutic formulations of pentahydroxyflavone glycoside, rutoside (RU), led us to investigate the ability of this molecule to modulate the release of various proinflammatory mediators from human activated macrophages in vitro and to ameliorate arthritic markers in a rat model.
RU was added simultaneously to human macrophages during their activation. Cells were then analyzed for inflammation-related gene expression using a specific array, and cell supernatants were collected to measure inflammatory mediators. RU was also injected into adjuvant-induced arthritic rats, and disease progression and body weight were evaluated until 50 days after injection. Sera and peritoneal macrophages were also collected to quantify the RU effect on various inflammatory markers.
RU inhibited inflammation-related gene expression in activated human macrophages and the release of nitric oxide, tumor necrosis factor-alpha, interleukin (IL)-1, and IL-6 from these cells. In a rat model, RU inhibited clinical signs of chronic arthritis, correlating with decreased levels of inflammatory cytokines detected in rat sera and macrophage supernatants.
Thus, RU may have clinical value in reducing inflammatory manifestations in human arthritis and other inflammatory diseases. |
| doi_str_mv | 10.1186/ar2372 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2374451</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A176677088</galeid><sourcerecordid>A176677088</sourcerecordid><originalsourceid>FETCH-LOGICAL-b539t-9da0241db5e04ab8759f41c764ce48bd3a1645d7ee051c43e15d132cb844b1913</originalsourceid><addsrcrecordid>eNp1Ul1rFDEUHUSxtepPkEGhb1OTTCbJvAilWBUKguhzuJPc2c0ySdZkZqHgjzfLLq0rSh5yufeccz-r6jUlV5Qq8R4SayV7Up1TLlUjWsGePtgdP6te5LwhhLGe8efVGVWsY4T059Wvb8scs7NYWzQJIWOu14uHUHswKW7XsMLGYnI7tLUL4wTewxzTfe3Rur2Vawgl5Lcp7grZTC44A1Od3SrkQqnBbpYdhLlxwS6myECa18nNLr-sno0wZXx1_C-qH7cfv998bu6-fvpyc33XDF3bz01vgTBO7dAh4TAo2fUjp0YKbpCrwbZABe-sRCQdNbxF2lnaMjMozgfa0_ai-nDQ3S5DKdtgmBNMepuch3SvIzh9GglurVdxp8tMOe_2Av1BYHDxPwKnERO9PqykcC-PyVP8uWCetXfZ4DRBwLhkzYjshZJtAb79C7iJSwplMJpRySVTQhbQuwNoBRPqspBY8pm9or6mUggpiVIFdfUPVHkWvTMx4OiK_4RwLLLsPOeE40NvlOj9gT128-bPUT7CjhfV_gYNU87L</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217472867</pqid></control><display><type>article</type><title>Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Kauss, Tina ; Moynet, Daniel ; Rambert, Jérôme ; Al-Kharrat, Abir ; Brajot, Stephane ; Thiolat, Denis ; Ennemany, Rachid ; Fawaz, Fawaz ; Mossalayi, M Djavad</creator><creatorcontrib>Kauss, Tina ; Moynet, Daniel ; Rambert, Jérôme ; Al-Kharrat, Abir ; Brajot, Stephane ; Thiolat, Denis ; Ennemany, Rachid ; Fawaz, Fawaz ; Mossalayi, M Djavad</creatorcontrib><description>Dietary flavonols may play an important role in the adjunct therapy of chronic inflammation. The availability of therapeutic formulations of pentahydroxyflavone glycoside, rutoside (RU), led us to investigate the ability of this molecule to modulate the release of various proinflammatory mediators from human activated macrophages in vitro and to ameliorate arthritic markers in a rat model.
RU was added simultaneously to human macrophages during their activation. Cells were then analyzed for inflammation-related gene expression using a specific array, and cell supernatants were collected to measure inflammatory mediators. RU was also injected into adjuvant-induced arthritic rats, and disease progression and body weight were evaluated until 50 days after injection. Sera and peritoneal macrophages were also collected to quantify the RU effect on various inflammatory markers.
RU inhibited inflammation-related gene expression in activated human macrophages and the release of nitric oxide, tumor necrosis factor-alpha, interleukin (IL)-1, and IL-6 from these cells. In a rat model, RU inhibited clinical signs of chronic arthritis, correlating with decreased levels of inflammatory cytokines detected in rat sera and macrophage supernatants.
Thus, RU may have clinical value in reducing inflammatory manifestations in human arthritis and other inflammatory diseases.</description><identifier>ISSN: 1478-6354</identifier><identifier>EISSN: 1478-6362</identifier><identifier>EISSN: 1478-6354</identifier><identifier>DOI: 10.1186/ar2372</identifier><identifier>PMID: 18252009</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject><![CDATA[Animals ; Arthritis ; Arthritis, Experimental - genetics ; Arthritis, Experimental - metabolism ; Arthritis, Experimental - pathology ; Arthritis, Experimental - physiopathology ; Body Weight - drug effects ; Care and treatment ; Cells, Cultured ; Chronic Disease ; Cytokines - antagonists & inhibitors ; Cytokines - genetics ; Dose-Response Relationship, Drug ; Female ; Health aspects ; Humans ; Inflammation ; Inflammation Mediators - antagonists & inhibitors ; Interleukin-1 - antagonists & inhibitors ; Interleukin-6 - antagonists & inhibitors ; Macrophages - drug effects ; Macrophages - metabolism ; Macrophages, Peritoneal - drug effects ; Macrophages, Peritoneal - metabolism ; Nitric Oxide - antagonists & inhibitors ; Rats ; Rats, Inbred Lew ; Rutin - administration & dosage ; Rutin - pharmacology ; Transcription, Genetic - drug effects ; Tumor Necrosis Factor-alpha - antagonists & inhibitors]]></subject><ispartof>Arthritis research & therapy, 2008-01, Vol.10 (1), p.R19-R19, Article R19</ispartof><rights>COPYRIGHT 2008 BioMed Central Ltd.</rights><rights>Copyright National Library of Medicine - MEDLINE Abstracts 2008</rights><rights>Copyright © 2008 Kauss et al.; licensee BioMed Central Ltd. 2008 Kauss et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b539t-9da0241db5e04ab8759f41c764ce48bd3a1645d7ee051c43e15d132cb844b1913</citedby><cites>FETCH-LOGICAL-b539t-9da0241db5e04ab8759f41c764ce48bd3a1645d7ee051c43e15d132cb844b1913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374451/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374451/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18252009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kauss, Tina</creatorcontrib><creatorcontrib>Moynet, Daniel</creatorcontrib><creatorcontrib>Rambert, Jérôme</creatorcontrib><creatorcontrib>Al-Kharrat, Abir</creatorcontrib><creatorcontrib>Brajot, Stephane</creatorcontrib><creatorcontrib>Thiolat, Denis</creatorcontrib><creatorcontrib>Ennemany, Rachid</creatorcontrib><creatorcontrib>Fawaz, Fawaz</creatorcontrib><creatorcontrib>Mossalayi, M Djavad</creatorcontrib><title>Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis</title><title>Arthritis research & therapy</title><addtitle>Arthritis Res Ther</addtitle><description>Dietary flavonols may play an important role in the adjunct therapy of chronic inflammation. The availability of therapeutic formulations of pentahydroxyflavone glycoside, rutoside (RU), led us to investigate the ability of this molecule to modulate the release of various proinflammatory mediators from human activated macrophages in vitro and to ameliorate arthritic markers in a rat model.
RU was added simultaneously to human macrophages during their activation. Cells were then analyzed for inflammation-related gene expression using a specific array, and cell supernatants were collected to measure inflammatory mediators. RU was also injected into adjuvant-induced arthritic rats, and disease progression and body weight were evaluated until 50 days after injection. Sera and peritoneal macrophages were also collected to quantify the RU effect on various inflammatory markers.
RU inhibited inflammation-related gene expression in activated human macrophages and the release of nitric oxide, tumor necrosis factor-alpha, interleukin (IL)-1, and IL-6 from these cells. In a rat model, RU inhibited clinical signs of chronic arthritis, correlating with decreased levels of inflammatory cytokines detected in rat sera and macrophage supernatants.
Thus, RU may have clinical value in reducing inflammatory manifestations in human arthritis and other inflammatory diseases.</description><subject>Animals</subject><subject>Arthritis</subject><subject>Arthritis, Experimental - genetics</subject><subject>Arthritis, Experimental - metabolism</subject><subject>Arthritis, Experimental - pathology</subject><subject>Arthritis, Experimental - physiopathology</subject><subject>Body Weight - drug effects</subject><subject>Care and treatment</subject><subject>Cells, Cultured</subject><subject>Chronic Disease</subject><subject>Cytokines - antagonists & inhibitors</subject><subject>Cytokines - genetics</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation Mediators - antagonists & inhibitors</subject><subject>Interleukin-1 - antagonists & inhibitors</subject><subject>Interleukin-6 - antagonists & inhibitors</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - metabolism</subject><subject>Macrophages, Peritoneal - drug effects</subject><subject>Macrophages, Peritoneal - metabolism</subject><subject>Nitric Oxide - antagonists & inhibitors</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Rutin - administration & dosage</subject><subject>Rutin - pharmacology</subject><subject>Transcription, Genetic - drug effects</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>1478-6354</issn><issn>1478-6362</issn><issn>1478-6354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1Ul1rFDEUHUSxtepPkEGhb1OTTCbJvAilWBUKguhzuJPc2c0ySdZkZqHgjzfLLq0rSh5yufeccz-r6jUlV5Qq8R4SayV7Up1TLlUjWsGePtgdP6te5LwhhLGe8efVGVWsY4T059Wvb8scs7NYWzQJIWOu14uHUHswKW7XsMLGYnI7tLUL4wTewxzTfe3Rur2Vawgl5Lcp7grZTC44A1Od3SrkQqnBbpYdhLlxwS6myECa18nNLr-sno0wZXx1_C-qH7cfv998bu6-fvpyc33XDF3bz01vgTBO7dAh4TAo2fUjp0YKbpCrwbZABe-sRCQdNbxF2lnaMjMozgfa0_ai-nDQ3S5DKdtgmBNMepuch3SvIzh9GglurVdxp8tMOe_2Av1BYHDxPwKnERO9PqykcC-PyVP8uWCetXfZ4DRBwLhkzYjshZJtAb79C7iJSwplMJpRySVTQhbQuwNoBRPqspBY8pm9or6mUggpiVIFdfUPVHkWvTMx4OiK_4RwLLLsPOeE40NvlOj9gT128-bPUT7CjhfV_gYNU87L</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Kauss, Tina</creator><creator>Moynet, Daniel</creator><creator>Rambert, Jérôme</creator><creator>Al-Kharrat, Abir</creator><creator>Brajot, Stephane</creator><creator>Thiolat, Denis</creator><creator>Ennemany, Rachid</creator><creator>Fawaz, Fawaz</creator><creator>Mossalayi, M Djavad</creator><general>BioMed Central Ltd</general><general>National Library of Medicine - MEDLINE Abstracts</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20080101</creationdate><title>Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis</title><author>Kauss, Tina ; Moynet, Daniel ; Rambert, Jérôme ; Al-Kharrat, Abir ; Brajot, Stephane ; Thiolat, Denis ; Ennemany, Rachid ; Fawaz, Fawaz ; Mossalayi, M Djavad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b539t-9da0241db5e04ab8759f41c764ce48bd3a1645d7ee051c43e15d132cb844b1913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Arthritis</topic><topic>Arthritis, Experimental - genetics</topic><topic>Arthritis, Experimental - metabolism</topic><topic>Arthritis, Experimental - pathology</topic><topic>Arthritis, Experimental - physiopathology</topic><topic>Body Weight - drug effects</topic><topic>Care and treatment</topic><topic>Cells, Cultured</topic><topic>Chronic Disease</topic><topic>Cytokines - antagonists & inhibitors</topic><topic>Cytokines - genetics</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation Mediators - antagonists & inhibitors</topic><topic>Interleukin-1 - antagonists & inhibitors</topic><topic>Interleukin-6 - antagonists & inhibitors</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - metabolism</topic><topic>Macrophages, Peritoneal - drug effects</topic><topic>Macrophages, Peritoneal - metabolism</topic><topic>Nitric Oxide - antagonists & inhibitors</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Rutin - administration & dosage</topic><topic>Rutin - pharmacology</topic><topic>Transcription, Genetic - drug effects</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kauss, Tina</creatorcontrib><creatorcontrib>Moynet, Daniel</creatorcontrib><creatorcontrib>Rambert, Jérôme</creatorcontrib><creatorcontrib>Al-Kharrat, Abir</creatorcontrib><creatorcontrib>Brajot, Stephane</creatorcontrib><creatorcontrib>Thiolat, Denis</creatorcontrib><creatorcontrib>Ennemany, Rachid</creatorcontrib><creatorcontrib>Fawaz, Fawaz</creatorcontrib><creatorcontrib>Mossalayi, M Djavad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis research & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kauss, Tina</au><au>Moynet, Daniel</au><au>Rambert, Jérôme</au><au>Al-Kharrat, Abir</au><au>Brajot, Stephane</au><au>Thiolat, Denis</au><au>Ennemany, Rachid</au><au>Fawaz, Fawaz</au><au>Mossalayi, M Djavad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis</atitle><jtitle>Arthritis research & therapy</jtitle><addtitle>Arthritis Res Ther</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>10</volume><issue>1</issue><spage>R19</spage><epage>R19</epage><pages>R19-R19</pages><artnum>R19</artnum><issn>1478-6354</issn><eissn>1478-6362</eissn><eissn>1478-6354</eissn><abstract>Dietary flavonols may play an important role in the adjunct therapy of chronic inflammation. The availability of therapeutic formulations of pentahydroxyflavone glycoside, rutoside (RU), led us to investigate the ability of this molecule to modulate the release of various proinflammatory mediators from human activated macrophages in vitro and to ameliorate arthritic markers in a rat model.
RU was added simultaneously to human macrophages during their activation. Cells were then analyzed for inflammation-related gene expression using a specific array, and cell supernatants were collected to measure inflammatory mediators. RU was also injected into adjuvant-induced arthritic rats, and disease progression and body weight were evaluated until 50 days after injection. Sera and peritoneal macrophages were also collected to quantify the RU effect on various inflammatory markers.
RU inhibited inflammation-related gene expression in activated human macrophages and the release of nitric oxide, tumor necrosis factor-alpha, interleukin (IL)-1, and IL-6 from these cells. In a rat model, RU inhibited clinical signs of chronic arthritis, correlating with decreased levels of inflammatory cytokines detected in rat sera and macrophage supernatants.
Thus, RU may have clinical value in reducing inflammatory manifestations in human arthritis and other inflammatory diseases.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>18252009</pmid><doi>10.1186/ar2372</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-6354 |
| ispartof | Arthritis research & therapy, 2008-01, Vol.10 (1), p.R19-R19, Article R19 |
| issn | 1478-6354 1478-6362 1478-6354 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2374451 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; SpringerLink Journals - AutoHoldings; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Animals Arthritis Arthritis, Experimental - genetics Arthritis, Experimental - metabolism Arthritis, Experimental - pathology Arthritis, Experimental - physiopathology Body Weight - drug effects Care and treatment Cells, Cultured Chronic Disease Cytokines - antagonists & inhibitors Cytokines - genetics Dose-Response Relationship, Drug Female Health aspects Humans Inflammation Inflammation Mediators - antagonists & inhibitors Interleukin-1 - antagonists & inhibitors Interleukin-6 - antagonists & inhibitors Macrophages - drug effects Macrophages - metabolism Macrophages, Peritoneal - drug effects Macrophages, Peritoneal - metabolism Nitric Oxide - antagonists & inhibitors Rats Rats, Inbred Lew Rutin - administration & dosage Rutin - pharmacology Transcription, Genetic - drug effects Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T12%3A26%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rutoside%20decreases%20human%20macrophage-derived%20inflammatory%20mediators%20and%20improves%20clinical%20signs%20in%20adjuvant-induced%20arthritis&rft.jtitle=Arthritis%20research%20&%20therapy&rft.au=Kauss,%20Tina&rft.date=2008-01-01&rft.volume=10&rft.issue=1&rft.spage=R19&rft.epage=R19&rft.pages=R19-R19&rft.artnum=R19&rft.issn=1478-6354&rft.eissn=1478-6362&rft_id=info:doi/10.1186/ar2372&rft_dat=%3Cgale_pubme%3EA176677088%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217472867&rft_id=info:pmid/18252009&rft_galeid=A176677088&rfr_iscdi=true |